Oncolytics Biotech (ONC) Scheduled to Post Earnings on Thursday

Oncolytics Biotech (TSE:ONC) will post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Oncolytics Biotech to post earnings of C($0.12) per share for the quarter.

Oncolytics Biotech (TSE:ONC) last released its earnings results on Thursday, March 7th. The company reported C($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of C($0.15) by C$0.10.

Oncolytics Biotech Stock Performance

Shares of ONC stock opened at C$1.54 on Thursday. The firm has a market capitalization of C$116.15 million, a price-to-earnings ratio of -3.76 and a beta of 1.49. The company has a 50 day moving average price of C$1.44 and a 200 day moving average price of C$1.70. Oncolytics Biotech has a one year low of C$1.20 and a one year high of C$4.49. The company has a debt-to-equity ratio of 1.54, a quick ratio of 8.86 and a current ratio of 9.01.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Raymond James set a C$3.00 target price on Oncolytics Biotech and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Oncolytics Biotech in a research note on Friday, January 12th.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.